Reanalysis of Popular Antidepressant Trial Uncovers Reporting Flaws
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Reanalysis of Popular Antidepressant Trial Uncovers Reporting Flaws
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
- A reanalysis of a study found that fluoxetine alone showed no measurable benefit over placebo in treating adolescent depression after 12 weeks
- Researchers uncovered 11 additional suicide-related events that were hidden or misclassified, bringing the total to 21 serious incidents
- Statistical tactics and selective reporting made fluoxetine appear safer and more effective than it really was in clinical trials
- A different reanalysis mentioned that adverse events and many side effects were minimized or excluded from the original reports
- Improving gut health, getting regular exercise, undergoing therapy, and optimizing vitamin D are viable approaches for treating depression
Pas encore de commentaire